#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA871407	B	Inhibition of PACAP receptor at 1 uM	Homo sapiens	1	ALA1138064	single protein format	Scientific Literature
2.	ALA911629	F	Activity at human VPAC2 receptor in CHO cells by measuring cAMP accumulation	Homo sapiens	2	ALA1138207	cell-based format	Scientific Literature
3.	ALA911644	B	Displacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cells	Homo sapiens	2	ALA1138207	cell-based format	Scientific Literature
4.	ALA2160805	F	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	Homo sapiens	4	ALA2157898	cell-based format	Scientific Literature
5.	ALA3106155	F	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	Homo sapiens	16	ALA3102798	cell-based format	Scientific Literature
6.	ALA3738746	B	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	Homo sapiens	4	ALA3734733	cell-based format	Scientific Literature
7.	ALA3738750	F	Activation of VPAC2 in human SH-SY5Y cells assessed as stimulation of forskolin-induced cAMP production at 10'-7 to 10'-5 M after 30 mins	Homo sapiens	3	ALA3734733	cell-based format	Scientific Literature
8.	ALA3880367	F	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged VIPR2 expressed in HEK293 cells co-expressing CAMYEL assessed as inhibition of VIP-induced cAMP accumulation at 0.5 uM preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay relative to control	Homo sapiens	101	ALA3879914	cell-based format	Patent Bioactivity Data
9.	ALA3880368	F	Antagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced cAMP accumulation incubated for 30 mins by HTRF assay	Homo sapiens	1	ALA3879914	cell-based format	Patent Bioactivity Data
10.	ALA3880369	F	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged VIPR2 expressed in CHO cells co-expressing CAMYEL assessed as inhibition of VIP-induced cAMP accumulation preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	Homo sapiens	1	ALA3879914	cell-based format	Patent Bioactivity Data
11.	ALA3880370	B	Antagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced beta-arrestin 2 binding incubated for 2 hrs by beta-galactosidase assay	Homo sapiens	1	ALA3879914	cell-based format	Patent Bioactivity Data
12.	ALA3880371	F	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged VIPR2 expressed in HEK293 cells co-expressing CAMYEL assessed as inhibition of VIP-induced cAMP accumulation at 5 uM preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay relative to control	Homo sapiens	101	ALA3879914	cell-based format	Patent Bioactivity Data
13.	ALA3880372	F	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged VIPR2 expressed in HEK293 cells co-expressing CAMYEL assessed as inhibition of VIP-induced cAMP accumulation at 1 uM preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay relative to control	Homo sapiens	101	ALA3879914	cell-based format	Patent Bioactivity Data
14.	ALA3880373	B	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding at 5 uM preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay relative to control	Homo sapiens	101	ALA3879914	cell-based format	Patent Bioactivity Data
15.	ALA3880374	B	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding at 1 uM preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay relative to control	Homo sapiens	101	ALA3879914	cell-based format	Patent Bioactivity Data
16.	ALA3880375	B	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding at 0.5 uM preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay relative to control	Homo sapiens	104	ALA3879914	cell-based format	Patent Bioactivity Data
17.	ALA3880376	B	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	Homo sapiens	57	ALA3879914	cell-based format	Patent Bioactivity Data
18.	ALA4257230	F	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	Homo sapiens	33	ALA4257221	cell-based format	Patent Bioactivity Data
19.	ALA4312673	B	Activity at human VPAC2 at 10 uM	Homo sapiens	1	ALA4311943	single protein format	Scientific Literature
20.	ALA4883617	B	PRESTO-Tango GPCRome screening (VIPR2)		1	ALA4507309	single protein format	Donated Chemical Probes - SGC Frankfurt